Stock Evaluator: Journey Medical Corporation (DERM)

Journey Medical Corporation DERM

$6.37 -0.08 -1.24%
July 31, 2026 4:00:00 PM EST November 10, 2021 Volume: 47,040
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Pharmaceuticals

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company’s marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.

Commentary & Analysis


Financial Summary

Share Statistics DERM Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $175.4 $579.1 26%
Shares Out (Mil) 27.3 43.0 35%
Institutional Ownership 79.4% 84.3% 49%
Float (Mil) 14.9 46.8 25%
Beta 1.04 0.62 62%
Avg Daily Volume (000s) 145 285 40%
Price Change
(52-week)
(16.1%) 63.8% 33%
Growth DERM Industry
Median
Percentile
(All Stocks)
Sales (5yr) 6.8% 6.7% 45%
Net Income (5yr) (32.9%) (1.4%) 12%
EPS (5yr) (24.2%) 14.9% 11
Dividends (5yr) 0.0% 0.0% 0%
Cash Flow (5yr) (17.0%) (14.9%) 42%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates na na na
Current EPS na na na
Month Ago EPS na na na
# Rev Up na na na
# Rev Down na na na
Three Months Ago EPS na na na
Year/Year Chg na na na
Financials DERM Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $65 $272 22%
Net Income (TTM) (Mil) ($10) ($11) 29%
EPS (TTM) ($0.373) ($0.500) 30%
Operating Cash Flow (TTM) (Mil) ($7) ($6) 23%
Net Cash Flow (TTM) (Mil) na $4 na
Long-Term Debt (Q1) (Mil) $23 $7 34%
Enterprise Value (Q1) (Mil) $173 $522 25%
Valuation DERM Industry
Median
Percentile
(All Stocks)
P/B 5.64 2.73 81%
P/E na 20.5 na
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) na 1.2 na
Ratios DERM Industry
Median
Percentile
(All Stocks)
Gross Margin 65.4% 65.9% 77%
Net Margin (14.8%) 0.7% 18%
ROA (10.9%) (24.6%) 25%
ROE (36.6%) (19.7%) 18%
Liabilities to Assets 66.3% 35.5% 61%
F-Score 5 3 51%

Journey Medical Corporation did not pass any screens on 7/31/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors